Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.
Employees - 40,
CEO - Dr. David J. Lennon Ph.D.,
Sector - Healthcare,
Country - US,
Market Cap - 93.74M
Altman ZScore(max is 10): 2.57, Piotroski Score(max is 10): 5, Working Capital: $220340000, Total Assets: $234002000, Retained Earnings: $-259637999, EBIT: -59850000, Total Liabilities: $12274000, Revenue: $27775000
- Current Price $1.99 - Analyst Target Price $2.00Ticker | WHWK |
Index | - |
Curent Price | 1.99 |
Change | 13.07% |
Market Cap | 93.74M |
Average Volume | 157.68K |
Income | 27.61M |
Sales | 27.77M |
Book Value/Share | 4.74 |
Cash/Share | 4.90 |
Dividend Est | - |
Dividend TTM | - |
Dividend Ex-Date | - |
Employees | 40 |
Moving Avg 20days | 21.92% |
Moving Avg 50days | 15.01% |
Moving Avg 200days | -6.95% |
Shares Outstanding | 46.78M |
Earnings Date | May 08 AMC |
Inst. Ownership | 48.88% |
Price/Earnings | 13.27 |
Forwad P/E | - |
PE Growth | 2.02 |
Price/Sales | 3.38 |
Price/Book | 0.42 |
Price/Cash | 0.41 |
Price/FCF | - |
Quick Ratio | 18.95 |
Current Ratio | 18.95 |
Debt/Equity | 0.00 |
Return on Assets | 16.00% |
Return on Equity | 17.69% |
Return on Investment | 12.45% |
Gross Margin | 88.72% |
Ops Margin | -217.92% |
Profit Margin | 99.42% |
RSI | 69.74 |
BETA(β) | 0.55 |
From 52week Low | 64.46% |
From 52week High | -47.80% |
EPS | 0.15 |
EPS next Year | -1.89 |
EPS next Qtr | 0.49 |
EPS this Year | 107.49% |
EPS next 5 Year | 6.57% |
EPS past 5 Year | 22.81% |
Sales past 5 Year | 246.60% |
EPS Y/Y | 106.40% |
Sales Y/Y | 16.51% |
EPS Q/Q | 369.77% |
Sales Q/Q | 33.48% |
Sales Surprise | - |
EPS Surprise | 497.83% |
ATR(14) | 0.14 |
Perf Week | 20.61% |
Perf Month | 28.39% |
Perf Quarter | -30.66% |
Perf Year | 3.92% |
Perf YTD | -36.93% |
Target Price | 2.00 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer